Published in J Pharmacol Exp Ther on October 27, 2004
Activities of mixed NOP and mu-opioid receptor ligands. Br J Pharmacol (2007) 1.30
SR 16435 [1-(1-(bicyclo[3.3.1]nonan-9-yl)piperidin-4-yl)indolin-2-one], a novel mixed nociceptin/orphanin FQ/mu-opioid receptor partial agonist: analgesic and rewarding properties in mice. J Pharmacol Exp Ther (2006) 1.08
Pharmacological profile of NOP receptors coupled with calcium signaling via the chimeric protein G alpha qi5. Naunyn Schmiedebergs Arch Pharmacol (2009) 0.95
In vitro and in vivo studies on UFP-112, a novel potent and long lasting agonist selective for the nociceptin/orphanin FQ receptor. Peptides (2007) 0.93
Differential effects of nociceptin/orphanin FQ (NOP) receptor agonists in acute versus chronic pain: studies with bifunctional NOP/μ receptor agonists in the sciatic nerve ligation chronic pain model in mice. J Pharmacol Exp Ther (2011) 0.91
The nociceptin/orphanin FQ receptor (NOP) as a target for drug abuse medications. Curr Top Med Chem (2011) 0.89
In vitro and in vivo pharmacological characterization of nociceptin/orphanin FQ tetrabranched derivatives. Br J Pharmacol (2014) 0.87
Large-scale association analysis identifies 13 new susceptibility loci for coronary artery disease. Nat Genet (2011) 13.25
Inheritance of coronary artery disease in men: an analysis of the role of the Y chromosome. Lancet (2012) 5.16
Structure of the nociceptin/orphanin FQ receptor in complex with a peptide mimetic. Nature (2012) 2.96
Pre-procedural fasting for coronary interventions: is it time to change practice? Heart (2014) 2.61
Cell stiffness is a biomarker of the metastatic potential of ovarian cancer cells. PLoS One (2012) 2.23
Solution structure of the Alzheimer amyloid beta-peptide (1-42) in an apolar microenvironment. Similarity with a virus fusion domain. Eur J Biochem (2002) 1.99
Sensory integration and the perceptual experience of persons with autism. J Autism Dev Disord (2006) 1.95
The burden of neuropathic pain: results from a cross-sectional survey. Eur J Pain (2006) 1.82
The tachykinin peptide family. Pharmacol Rev (2002) 1.82
CD44 attenuates metastatic invasion during breast cancer progression. Cancer Res (2005) 1.72
The alpha-to-beta conformational transition of Alzheimer's Abeta-(1-42) peptide in aqueous media is reversible: a step by step conformational analysis suggests the location of beta conformation seeding. Chembiochem (2006) 1.70
Novel pathogenic mechanism and therapeutic approaches to angioedema associated with C1 inhibitor deficiency. J Allergy Clin Immunol (2009) 1.70
Brain-derived neurotrophic factor mRNA and protein are targeted to discrete dendritic laminas by events that trigger epileptogenesis. J Neurosci (2004) 1.51
A review of mathematical models used to determine sperm donor limits for infertility treatment. Fertil Steril (2007) 1.50
The epithelial sodium channel γ-subunit gene and blood pressure: family based association, renal gene expression, and physiological analyses. Hypertension (2011) 1.50
Bradykinin receptor ligands: therapeutic perspectives. Nat Rev Drug Discov (2004) 1.44
Evaluation of the Dmt-Tic pharmacophore: conversion of a potent delta-opioid receptor antagonist into a potent delta agonist and ligands with mixed properties. J Med Chem (2002) 1.40
Dmt and opioid peptides: a potent alliance. Biopolymers (2003) 1.40
Cytokine blockade attenuates sympathoexcitation in heart failure: cross-talk between nNOS, AT-1R and cytokines in the hypothalamic paraventricular nucleus. Eur J Heart Fail (2008) 1.28
The chemokine Bv8/prokineticin 2 is up-regulated in inflammatory granulocytes and modulates inflammatory pain. Proc Natl Acad Sci U S A (2009) 1.24
Potent delta-opioid receptor agonists containing the Dmt-Tic pharmacophore. J Med Chem (2002) 1.23
Potential role of uric acid in metabolic syndrome, hypertension, kidney injury, and cardiovascular diseases: is it time for reappraisal? Curr Hypertens Rep (2013) 1.20
Localized delivery of fibroblast growth factor-2 and brain-derived neurotrophic factor reduces spontaneous seizures in an epilepsy model. Proc Natl Acad Sci U S A (2009) 1.18
Ethnic differences in thermal pain responses: a comparison of South Asian and White British healthy males. Pain (2005) 1.16
Effects of human urotensin II in isolated vessels of various species; comparison with other vasoactive agents. Naunyn Schmiedebergs Arch Pharmacol (2001) 1.14
[Nphe1,Arg14,Lys15]nociceptin-NH2, a novel potent and selective antagonist of the nociceptin/orphanin FQ receptor. Br J Pharmacol (2002) 1.14
Structure-activity studies on neuropeptide S: identification of the amino acid residues crucial for receptor activation. J Biol Chem (2006) 1.13
Antagonism of metabotropic glutamate receptor type 5 attenuates l-DOPA-induced dyskinesia and its molecular and neurochemical correlates in a rat model of Parkinson's disease. J Neurochem (2007) 1.12
Interaction of sweet proteins with their receptor. A conformational study of peptides corresponding to loops of brazzein, monellin and thaumatin. Eur J Biochem (2004) 1.11
Neurobiology, pharmacology, and medicinal chemistry of neuropeptide S and its receptor. Med Res Rev (2010) 1.09
Pharmacological characterization of the nociceptin/orphanin FQ receptor antagonist SB-612111 [(-)-cis-1-methyl-7-[[4-(2,6-dichlorophenyl)piperidin-1-yl]methyl]-6,7,8,9-tetrahydro-5H-benzocyclohepten-5-ol]: in vivo studies. J Pharmacol Exp Ther (2007) 1.09
Targeting kinin B(1) receptor for therapeutic neovascularization. Circulation (2002) 1.08
Anxiolytic-like effect of neuropeptide S in the rat defensive burying. Peptides (2008) 1.08
Synthesis and biological activity of human neuropeptide S analogues modified in position 5: identification of potent and pure neuropeptide S receptor antagonists. J Med Chem (2009) 1.08
Lack of "immunological fitness" during fasting in metabolically challenged animals. J Lipid Res (2012) 1.08
Blockade of nociceptin/orphanin FQ transmission attenuates symptoms and neurodegeneration associated with Parkinson's disease. J Neurosci (2005) 1.06
Long-lasting antinociceptive spinal effects in primates of the novel nociceptin/orphanin FQ receptor agonist UFP-112. Pain (2009) 1.05
Anxiolytic- and antidepressant-like activities of H-Dmt-Tic-NH-CH(CH2-COOH)-Bid (UFP-512), a novel selective delta opioid receptor agonist. Peptides (2007) 1.05
In vitro and in vivo pharmacological characterization of the neuropeptide s receptor antagonist [D-Cys(tBu)5]neuropeptide S. J Pharmacol Exp Ther (2008) 1.05
Urantide mimics urotensin-II induced calcium release in cells expressing recombinant UT receptors. Eur J Pharmacol (2004) 1.04
Solution structure of amyloid beta-peptide (25-35) in different media. J Med Chem (2004) 1.04
Exome sequencing and directed clinical phenotyping diagnose cholesterol ester storage disease presenting as autosomal recessive hypercholesterolemia. Arterioscler Thromb Vasc Biol (2013) 1.03
Angiotensin II reduces food intake by altering orexigenic neuropeptide expression in the mouse hypothalamus. Endocrinology (2012) 1.03
Hippocampal FGF-2 and BDNF overexpression attenuates epileptogenesis-associated neuroinflammation and reduces spontaneous recurrent seizures. J Neuroinflammation (2010) 1.02
6-N,N-dimethylamino-2,3-naphthalimide: a new environment-sensitive fluorescent probe in delta- and mu-selective opioid peptides. J Med Chem (2006) 1.02
Clinical characteristics and pain management among patients with painful peripheral neuropathic disorders in general practice settings. Eur J Pain (2006) 1.02
In vivo evidence for a differential contribution of striatal and nigral D1 and D2 receptors to L-DOPA induced dyskinesia and the accompanying surge of nigral amino acid levels. Neurobiol Dis (2011) 1.01
UFP-101, a peptide antagonist selective for the nociceptin/orphanin FQ receptor. CNS Drug Rev (2005) 1.01
Oxaliplatin in combination with 5-fluorouracil (5-FU) and leucovorin (LV) in patients with metastatic gastric cancer (MGC). Am J Clin Oncol (2006) 1.01
New opioid designed multiple ligand from Dmt-Tic and morphinan pharmacophores. J Med Chem (2006) 1.00